Shimabukuro, Tom T.

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., et al. (2021) · New England Journal of Medicine

COVID-19 Impact on ReproductionSARS-CoV-2 and COVID-19 Research

Cited by 927

Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices — United States, June 2021

Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., Broder, K. R., Gee, J., Weintraub, E., Shimabukuro, T., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

Viral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 Research

Cited by 587

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA

SARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 475

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 395

The MMR Vaccine and Autism

DeStefano, F., & Shimabukuro, T. T. (2019) · Annual Review of Virology

Vaccine Coverage and HesitancyVirology and Viral Diseases

Cited by 128

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.

Arana, J. E., Harrington, T., Cano, M., Lewis, P., Mba-Jonas, A., Rongxia, L., Stewart, B., Markowitz, L. E., & Shimabukuro, T. T. (2018) · Vaccine

Cervical Cancer and HPV ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 72

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.

Donahue, J. G., Kieke, B. A., King, J. P., Mascola, M. A., Shimabukuro, T. T., DeStefano, F., Hanson, K. E., McClure, D. L., Olaiya, O., Glanz, J. M., et al. (2019) · Vaccine

Influenza Virus Research StudiesPharmacovigilance and Adverse Drug Reactions

Cited by 59

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system

Chapin-Bardales, J., Myers, T., Gee, J., Shay, D. K., Marquez, P., Baggs, J., Zhang, B., Licata, C., & Shimabukuro, T. T. (2021) · Vaccine

SARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 23